These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Fracture risk associated with parkinsonism and anti-Parkinson drugs. Vestergaard P; Rejnmark L; Mosekilde L Calcif Tissue Int; 2007 Sep; 81(3):153-61. PubMed ID: 17705047 [TBL] [Abstract][Full Text] [Related]
29. [Prevention and treatment of fluctuations in patients with Parkinson's disease]. Ludin HP; Surber Ch Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589 [TBL] [Abstract][Full Text] [Related]
30. [Dopaminergic agonists in the treatment of Parkinson's disease]. Supiot F; Sternon J; Zegers de Beyl D Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495 [TBL] [Abstract][Full Text] [Related]
34. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports. Joseph CL; Siple J; McWhorter K; Camicioli R J Am Geriatr Soc; 1995 Jan; 43(1):47-50. PubMed ID: 7806739 [No Abstract] [Full Text] [Related]
35. [Pharmacological treatment of parkinsonism]. Friedman A Neurol Neurochir Pol; 1977; 11(6):689-93. PubMed ID: 600352 [No Abstract] [Full Text] [Related]
36. [Various kinds of antiparkinson agents and their characteristics]. Nakatsuka A; Nomoto M Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1419-25. PubMed ID: 13677889 [No Abstract] [Full Text] [Related]
37. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Caslake R; Macleod A; Ives N; Stowe R; Counsell C Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381 [TBL] [Abstract][Full Text] [Related]
38. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Kaakkola S Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464 [TBL] [Abstract][Full Text] [Related]
39. Agonists versus levodopa in PD: the thrilla of whitha. Montgomery EB Neurology; 2003 Nov; 61(10):1462; author reply 1462-3. PubMed ID: 14638991 [No Abstract] [Full Text] [Related]
40. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Joutsa J; Martikainen K; Vahlberg T; Kaasinen V Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]